# Avidity Biosciences (RNA) Stock Price, News & Catalysts
Canonical URL: https://biopharmsignal.com/company/RNA
## Company Profile
- Ticker: RNA
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
## Stock Data
- Close: 14.19 USD
- Market cap: 209544126.75 USD
- Last updated: 2026-09-04
## Business Overview
Avidity Biosciences is an RNA-targeting company focused on delivering therapies to muscle and other tissues using its antibody oligo conjugate platform. Its story is built around targeted RNA delivery and disease-specific programs.
## Why The Stock Is Moving

As of Sep 4, 2026, RNA closed down 2.81% at $14.19. No new same-company headline was identified in the current news window.

## Geographic Base

Headquartered in the United States and listed on NASDAQ, Avidity sits in advanced biotechnology.

## Business Model

The company depends on platform validation, clinical data, and the promise of targeted RNA delivery to hard-to-reach tissues.

## Landscape Position

Avidity is one of the most interesting RNA-delivery names because platform success could unlock multiple disease areas.

## Future Catalysts

- Avidity Biosciences's catalysts are AOC 1001 and the rest of its muscle-disease programs, where human data keep validating the delivery platform. The market will care about whether the platform keeps producing convincing in-human signals.

## Recent News
- 2026-02-27 14:16 EST — [Novartis successfully completes acquisition of Avidity Biosciences, strengthening late-stage neuroscience pipeline and advancing xRNA strategy](https://biopharmsignal.com/news/RNA/novartis-successfully-completes-acquisition-of-avidity-biosciences-strengthening-late-stage-neuroscience-pipeline-and-advancing-xrna-strategy) — Source: Avidity Biosciences
- 2026-02-26 21:02 EST — [Avidity Biosciences Announces Multiple Upcoming Presentations at 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference](https://biopharmsignal.com/news/RNA/avidity-biosciences-announces-multiple-upcoming-presentations-at-2026-muscular-dystrophy-association-mda-clinical-and-scientific-conference) — Source: Avidity Biosciences
- 2026-02-23 13:00 EST — [Avidity Biosciences Announces Intention to Adjourn and Reconvene Special Meeting of Stockholders](https://biopharmsignal.com/news/RNA/avidity-biosciences-announces-intention-to-adjourn-and-reconvene-special-meeting-of-stockholders) — Source: Avidity Biosciences
- 2026-02-18 22:00 EST — [The New England Journal of Medicine Publishes Results from Phase 1/2 MARINA® Trial of Delpacibart Etedesiran (del-desiran) for Treatment of Myotonic Dystrophy Type 1](https://biopharmsignal.com/news/RNA/the-new-england-journal-of-medicine-publishes-results-from-phase-1-2-marinar-trial-of-delpacibart-etedesiran-del-desiran-for-treatment-of-myotonic-dystrophy-type-1) — Source: Avidity Biosciences
- 2026-02-03 02:44 EST — [Avidity Biosciences Announces Expected Record Date for Spin-Off](https://biopharmsignal.com/news/RNA/avidity-biosciences-announces-expected-record-date-for-spin-off) — Source: Avidity Biosciences